![]() | ![]() |
Formats:
|
||||||||||||||||||||||||||||||||||||||||||
Copyright : © 2006 Zhai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Drosophila NMNAT Maintains Neural Integrity Independent of Its NAD Synthesis Activity 1Howard Hughes Medical Institute, Baylor College of Medicine, Houston, Texas, United States of America 2Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, United States of America 3Program in Developmental Biology, Baylor College of Medicine, Houston, Texas, United States of America Barry Dickson, Academic Editor Austrian Academy of Sciences, Austria * To whom correspondence should be addressed. E-mail: hbellen/at/bcm.edu Received July 28, 2006; Accepted September 29, 2006. See "How to Protect Fly Photoreceptors" , e438. This article has been cited by other articles in PMC.Abstract Wallerian degeneration refers to a loss of the distal part of an axon after nerve injury. Wallerian degeneration slow (Wlds) mice overexpress a chimeric protein containing the NAD synthase NMNAT (nicotinamide mononucleotide adenylyltransferase 1) and exhibit a delay in axonal degeneration. Currently, conflicting evidence raises questions as to whether NMNAT is the protecting factor and whether its enzymatic activity is required for such a possible function. Importantly, the link between nmnat and axon degeneration is at present solely based on overexpression studies of enzymatically active protein. Here we use the visual system of Drosophila as a model system to address these issues. We have isolated the first nmnat mutations in a multicellular organism in a forward genetic screen for synapse malfunction in Drosophila. Loss of nmnat causes a rapid and severe neurodegeneration that can be attenuated by blocking neuronal activity. Furthermore, in vivo neuronal expression of mutated nmnat shows that enzymatically inactive NMNAT protein retains strong neuroprotective effects and rescues the degeneration phenotype caused by loss of nmnat. Our data indicate an NAD-independent requirement of NMNAT for maintaining neuronal integrity that can be exploited to protect neurons from neuronal activity-induced degeneration by overexpression of the protein. Introduction Following nerve injury, distal axons and synaptic terminals undergo Wallerian degeneration within 48 h [1]. This process occurs in both the central and peripheral nervous systems and has several key features: (1) the distal stump of an injured axon loses its ability to transmit action potentials; (2) the axon and synaptic terminal become fragmented; (3) the cytoskeleton undergoes granular degeneration; and (4) the axonal and nerve terminal debris are removed by Schwann cells and invading macrophages [2]. Recent studies have started to unveil the molecular mechanisms of Wallerian degeneration. Inhibiting ubiquitination delays axon degeneration, suggesting the involvement of ubiquitin-mediated proteasomal degradation in the early stages of Wallerian degeneration [3]. In addition, studies have suggested that Wallerian degeneration is distinct from the apoptosis pathway, because caspases are not involved in Wallerian degeneration, and overexpression of apoptosis-inhibiting factors and mutations that block apoptosis fail to prevent axonal degeneration [4–6]. The discovery of the slow Wallerian degeneration mutant (Wlds) mouse, in which Wallerian degeneration is delayed by 2–3 wk, has provided a genetic inroad to study the mechanisms of deterioration and protection in axonal degeneration [7–10]. The pronounced delay in degeneration is caused by a tandem triplication of an 85-kilobase (kb) region, resulting in the overexpression of a chimeric Ube4b/Nmnat gene, which contains the amino terminal 70–amino acid fragment of Ube4b (ubiquitination factor E4B), the entire coding sequence of Nmnat1, and a unique 18–amino acid linking region translated from the 5′ untranslated region (UTR) of Nmnat1 [11,12]. Overexpression of the fusion protein in transgenic mice and rats reproduces the WldS phenotype [12,13], and recent studies show that overexpression of this fusion protein in Drosophila also protects axons from degeneration [14]. However, there are conflicting reports as to whether Nmnat1 alone is the protective factor [15–18], because transgenic mice overexpressing Nmnat1 do not exhibit protection from Wallerian degeneration [15,16]. In contrast, a detailed analysis of Wlds chimeric protein in the central nervous system (CNS) suggests that the increased level of Nmnat1 is significant in Wlds mice and that there is no obvious change in ubiquitination. Hence, its protective effects seem to be unrelated to the ubiquitination function of Ube4b [17]. In Drosophila, overexpression of nmnat can delay axonal degeneration [18]. The role of Ube4b remains controversial, however, as transfection of N70-Ube4b in cultured neurons does not produce a protective phenotype [19]. On the other hand, a recent report indicates that N70-Ube4b binds an important proteasomal chaperone (VCP) and relocates it to the nucleus [20]. Hence, it remains to be established whether N70-Ube4b is sufficient and/or necessary for a protective phenotype. Two in vitro studies pinpoint Nmnat1 as the protective agent and suggest that it acts either in the nucleus [19] or locally in axons [21]. Although both in vitro studies indicate a requirement of NAD for the protective effect, Wlds mice do not exhibit increased NAD levels [12]. This finding suggests either that local fluctuation of NAD levels is under the detection limit or that the Nmnat1 protein may have additional functions beyond NAD synthesis. Understanding the normal neuronal function of endogenous Nmnat in vivo is crucial to unveiling the mechanisms of neural degeneration and neural protection offered by Wlds protein. Here we show that loss of Drosophila nmnat causes severe neuronal and synaptic degeneration without affecting neural development. Importantly, this nmnat-dependent degeneration in photoreceptors can be attenuated by blocking phototransduction. NMNAT therefore functions to protect against activity-induced deterioration under normal conditions, and overexpression of NMNAT protects neurons from excessive activity-induced degeneration. This role is independent of its NAD synthesis activity, because overexpression of NMNAT protein with less than 1% activity can rescue the degeneration caused by loss of nmnat and has strong protective effects. We conclude that NMNAT is required to maintain neuronal integrity independent of its NAD synthesis function. Results Drosophila nmnat Is a Homolog of Mouse Nmnat1 Overexpressed in Wlds To identify genes that are involved in synapse development and function, we carried out a forward genetic screen using the eyFLP system [22–24]. The eyFLP system allows screening of flies that are homozygous for lethal mutations in the visual system but heterozygous in the rest of the animal [25]. Our primary screen was based on isolating ethyl methanesulfonate (EMS)-induced mutants that fail in a phototaxis assay, followed by screening for defects in electroretinograms (ERGs) and assessing morphological defects of photoreceptor axons and terminals [22]. We screened 210,000 flies and isolated 7,500 flies with grossly normal eye morphology that phototax poorly [26]. We next subjected the flies to ERG tests and isolated 450 mutants with abnormal ERG responses. Subsequent complementation tests yielded 64 complementation groups with two or more alleles. The Drosophila compound eye consists of 800 unit eyes, or ommatidia, each of which contains eight photoreceptors. Photoreceptors 1–6 (R1–R6) project to the first optic neuropil, or lamina, whereas R7 and R8 project deeper into the brain [27]. To isolate genes that specifically regulate synapse assembly and maintenance, we carried out a systematic transmission electron microscopy (TEM) analysis to uncover mutants with abnormal synapse structure in R1–R6 terminals [28]. Out of 60 mutants analyzed by TEM, two homozygous lethal mutations with abnormal active zone morphology that fail to complement each other (3R41 and 3R42) were isolated. As shown in Figure 1
To identify the molecular lesions of the two alleles of 3R4, we mapped the lethality associated with this complementation group using P element mapping [30]. Fine mapping with five P elements pinpointed a 50-kb region at cytological location 96B11 (Figure 2
The nonsense mutations in both alleles map to the C-terminal half of the predicted protein (Figure 2 CG13645 encodes NMNAT, a nicotinamide mononucleotide adenylyltransferase, which is a conserved, essential enzyme in most organisms. In humans, three isoforms, NMNAT1, −2, and −3, have been cloned, and their enzymatic properties have been analyzed [32–35]. There are also three predicted genes in the mouse, but only Nmnat1 has been characterized, mostly as part of the chimeric Wlds protein. Drosophila CG13645 is equally homologous to mouse and human NMNAT1, −2, or −3 with approximately 45% identity over the entire protein (Figure 2 Both mouse and human NMNAT1 have been shown to primarily localize to nuclei [17,32], whereas human NMNAT3 is present in the cytoplasm and mitochondria [35]. To characterize the localization of the NMNAT protein, we generated a polyclonal antibody against the full-length protein. The specificity of the antibody was verified in mosaic clones of Δ4790–1 or Δ4790–2 in eye discs (Figure S2). Mutant patches of nmnat1 or nmnat2 also lack antibody staining at a similar level as mutant patches of Δ4790–1 or Δ4790–2 (Figure S2), suggesting nonsense-mediated decay of the transcripts in both EMS alleles, further supporting the genetic data, which indicate that both EMS alleles are null alleles or severe hypomorphs. The antibody enabled us to examine the protein expression pattern by immunohistochemistry in wild-type animals (Figure 3
Loss of nmnat Causes Severe Early-Onset Neuronal Degeneration The reduced capability of nmnat mutant photoreceptors to respond to light, as revealed by ERG, can have several underlying causes: a defect in the phototransduction cascade, or a defect of the structural components of the phototransduction machinery, e.g., in rhabdomeres, the membrane stack in which the phototransduction components reside. We therefore examined the morphology of mutant retinae. The regular organization pattern of ommatidia can be visualized in a retina cross-section (Figure 4
To assess whether the development of the photoreceptors and accessory cells are affected in nmnat mutant eyes, we compared the morphology of mutant photoreceptors with neighboring wild-type cells by immunofluorescence labeling with several markers. We immunolabeled with antibodies against Actin to reveal rhabdomere structures, Armadillo to reveal the presence and morphology of adherence junctions between photoreceptors, and NMNAT to identify mutant cells. Photoreceptor subtype specification and differentiation are mostly completed by 50% of pupal development [40]. We therefore stained pupal eyes at both 30% and 50% of development and observed no morphological difference between mutant and wild-type tissue (Figure 5
Neurodegeneration Caused by Loss of nmnat Is Enhanced by Activity In an attempt to dissect the mechanisms underlying the neurodegeneration of mutant photoreceptors, we first tested whether the degeneration is light dependent, because a common cause for retinal degeneration is light stimulation [41,42]. Indeed, when flies with nmnat mutant photoreceptors are raised in the dark and sectioned at 1 d of age for TEM, they exhibit an overall normal organization of ommatidia similar to wild-type controls (Figure 6
To further establish whether neuronal activity is mediating the degenerative process, we tested whether mutants that impair the phototransduction cascade partially protect photoreceptors from neurodegeneration induced by the loss of nmnat. norpA (no receptor potential A) encodes a phospholipase C, which is required for phototransduction [43]. In norpAP24 mutants, phototransduction is blocked [43–45]. We find that in photoreceptors mutant for both norpAP24 and nmnat, neurodegeneration is partially suppressed (Figure 7
Next, we tested whether neural degeneration in nmnat mutant photoreceptors is related to apoptosis. If so, neuronal degeneration should be suppressed by proteins that inhibit apoptosis. We therefore expressed the apoptosis-inhibiting factor P35 [46] in nmnat mutant photoreceptors. We find that P35 expression does not suppress any phenotype associated with the loss of nmnat (Figures 7 Enzymatically Inactive NMNAT Rescues Neurodegeneration In an in vitro culture system, NAD synthesis is required for the Wlds protein to delay axon degeneration [19], and exogenous local application of NAD can prevent axon degeneration [21]. On the other hand, NAD levels were shown to be unchanged in Wlds axons that show delayed degeneration [12]. If the protective effect of Wlds and NMNAT occurs through enzymatic activity and hence NAD production, enzymatically inactive NMNAT should not rescue degeneration. To test this hypothesis, we generated transgenic flies that encode two different versions of enzymatically inactive NMNAT, nmnat-H30A, in which the catalytic center is mutated, and nmnat-WR, in which two key residues required for substrate binding are mutated. Both proteins have approximately 1% or less enzymatic activity of the wild-type protein in vitro (Figure 2
Interestingly, when we express wild-type NMNAT or enzymatically inactive NMNAT in the entire mutant animal using a ubiquitous driver (actin-GAL4), only the wild-type NMNAT is able to rescue the mutant animal to adulthood (Table S1). These data strongly suggest that the mutant enzymes lack activity in vivo and in vitro, and that NMNAT is a multifunctional protein that has two independent roles: NAD synthesis, which is required for viability, and a NAD-independent function that protects against neuronal activity-induced degeneration in mature photoreceptors. Overexpression of nmnat Protects against Excessive Activity-Induced Neurodegeneration Delayed Wallerian degeneration in Wlds mice demonstrates the protective effect of the chimeric gene Ube4b/Nmnat [12]. To investigate if overexpression of Drosophila nmnat has protective effects, we tested enzymatically active and inactive forms in hyperactivity-induced neurodegeneration. First, we overexpressed nmnat in the retinal degeneration mutants, rdgA and trpP365 [36,39,47]. It has been shown that in both rdgA and trpP365 mutant photoreceptors, retinal degeneration is caused by constitutive activation of Trp channels [38,39,48,49]. The primary phenotypes of both mutants are loss of rhabdomeres, disorganization of ommatidia, and vacuolarization throughout the retina and photoreceptors (Figures 9
In a second paradigm, we induced photoreceptor degeneration by exposing wild-type flies to constant intense light, a strong environmental insult that induces neurodegeneration [50–52]. Thirty days of constant, intense light exposure induces numerous small, as well as very large, vacuoles in wild-type retinae, and a reduced number of rhabdomeres (Figure 9 Discussion Here we report the identification and characterization of Drosophila nmnat and the first mutant analysis of nmnat in any multicellular organism. Our data reveal an essential neuronal protective function for nmnat, which is required for neurons to sustain normal neuronal activity. This function is independent of its enzymatic activity and can be exploited to protect neurons against activity-induced neurodegeneration. Maintaining Neuronal Integrity Our mutant analyses provide the first evidence that neuroprotection is a normal function of the endogenous protein, in contrast to previous overexpression reports [16,18]. Several lines of evidence support a role of NMNAT in protecting adult neurons against activity-induced degeneration. First, in the absence of nmnat, darkness delays the degeneration process of photoreceptors significantly. Second, mutations that impair components of the phototransduction cascade partially suppress the degeneration caused by loss of nmnat. Third, mutants in which photoreceptors degenerate due to constitutive phototransduction (rdgA and trpP365) [38,39,48], are partially protected by overexpression of nmnat. Finally, overexpression of nmnat in flies that are exposed to intense light potently protects against neuronal degeneration. These observations provide evidence that NMNAT functions to maintain the integrity of mature neurons by protecting them from use-dependent degeneration. This protection is likely to be independent of the NAD synthesis activity of NMNAT, because enzymatically inactive NMNAT proteins protect as effectively as the wild-type protein. Hence, our data indicate that a normal neuronal function of nmnat is to protect from activity-induced neurodegeneration. It is possible that the endogenous level of NMNAT is only sufficient to cope with the deterioration caused by normal levels of neuronal activity, but not enough for injury, which would require higher levels of restorative NMNAT. We propose that in the absence of NMNAT, the deterioration caused by normal activity cannot be overcome and is enough to induce degeneration. Is NAD Required for the Protective Effect? The normal development of nmnat mutant eyes suggests that nmnat is not required for neuronal specification, differentiation, axon pathfinding, or synapse formation. Given that NAD is required for cell survival, it is likely that NAD production by other enzymes compensates for the NAD synthesis function of nmnat, because NMNAT catalyzes one of the salvage pathways of NAD synthesis [53]. The de novo and alternative synthesis pathways are catalyzed by enzymes including NAase (nicotinamidase), NaPRTase (nicotinamide phosphoribosyltransferase), and NADS (NAD synthase), and there are predicted genes with each of these enzymatic activities in the fly genome [53] (see Figure S4). It has been shown in an in vitro culture system that NAD can protect injured axons from degeneration [19,21]. However, this protective effect is not specific to NAD, because pyruvate or EGTA have similar effects in the same studies [21]. It is equally possible that exogenously applied NAD can “free up” NMNAT from its NAD synthesis function and allow more NMNAT to engage in the protective function, thereby delaying degeneration. More puzzlingly, Araki et al. [19] showed that enzymatically inactive NMNAT bearing a mutant substrate binding motif (W170A) cannot delay axon degeneration. Mutation of the equivalent substrate binding motif of the Drosophila homolog in our assay reduced its activity to 10.8% of wild type (Figure 2 If the neuroprotective effect of MNNAT/Wlds is independent from its NAD synthesis activity, what might be the underlying molecular mechanism? Studies of several neurodegenerative diseases suggest that ubiquitin-mediated proteasome degradation and chaperone-mediated protein folding may play an important role in these degenerative processes [3,54–61]. Studies of a Drosophila model of Wallerian degeneration also indicate a protective effect by inhibiting ubiquitination [14]. Interestingly, the N-terminal part of the Wlds fusion protein N70-Ube4b is able to bind an important proteasomal chaperone (VCP) in vitro, and relocates it to the nucleus in cultured cells, suggesting a potential role for chaperones [20]. In conclusion, our genetic and functional analyses present evidence that, in addition to its NAD synthesis activity, a neuronal function of nmnat is to maintain neuronal integrity under normal conditions, and neuronal activity potentiates the degeneration that occurs when Nmnat is lost. By extension, more NMNAT protects neurons from neuronal activity induced degeneration. This activity, which is enzyme independent, indicates that the protein has two independent functions: NAD synthesis and maintenance of neuronal integrity. Materials and Methods Drosophila strains and conditions of culture. Flies were reared at room temperature in ambient light under a normal 12-h light/dark cycle. For dark-rearing experiments, flies were kept in complete darkness from the first instar larval stage onwards. For pupal staging experiments, flies were reared at 25 °C (100% pupal development corresponds to 103 h). Antibody production. The full-length cDNA was cloned into the pET28a (Invitrogen, Carlsbad, California, United States) vector for protein expression (gift of S. Wu). The cDNA fragment was cloned into EcoRI and NotI restriction sites using PCR primers that introduced those sites into the cDNA fragment as described for the cDNA rescue construct. Guinea pig antibodies against this domain were raised by Cocalico Biologicals (Reamstown, Pennsylvania, United States) using the purified recombinant protein. The polyclonal antisera were purified using the Protein A IgG Purification kit (Pierce Biotechnology, Rockford, Illinois, United States). Antibody specificity was confirmed by lack of staining in mutant clonal tissue incubated with anti-NMNAT (Figures 4 Drosophila strains, mutagenesis, and screen. Construction of rescue constructs and transgenic flies. Our genomic rescue construct consists of the nmnat genomic locus flanked by 0.4 kb of upstream genomic sequence and 0.5 kb of downstream sequence. The following primers were used to amplify this sequence from a clone in P1 phage library containing the CG13645 locus: primer1 5′-accgaattcgagcaggagcccgccacac-3′ and primer 2 5′-ataagaatgcggccgcgtggactcttccaagggaagcaagc-3′. Primer 1 contains an EcoRI site and primer 2 contains a NotI site to facilitate cloning. After sequence verification, the genomic fragment was cloned into the vector pP{CaSpeR-4}, and transgenic flies were generated. For cDNA rescue experiments, we cloned the full coding sequence of cDNA clone AT23490 (Drosophila Gene Collection, http://www.fruitfly.org/DGC/index.html) into pP{UAST} and pP{UAST-HA} (gift from B. Tavsanli), and generated several transgenic lines. The following primers were used to introduce EcoRI and NotI sites at the ends of the nmnat coding sequence for ease of cloning: 5′–CCGGAATTCATGTCAGCATTCATCGAGGAAAC-3′ and 5′–TTTTCCTTTTGCGGCCGCAGAGTCGCATTCGGTCGGAGCCG-3′. Site-directed mutagenesis and generation of recombinant protein. Inactive enzyme was created by site-directed mutagenesis of full-length nmnat cDNA in pET28a vector using QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, California, United States). The H30A, W98G, and R224A mutations were made by one round of mutagenesis, and the WR double mutation was made by sequential mutagenesis. The recombinant protein was generated, and the protein concentration was measured by Bradford assay (BioRad, Hercules, California, United States). The mutant cDNAs nmnat-H30A and nmnat-WR were subcloned into pP{UAST}, and transgenic lines were generated. NMNAT activity assay. Activity of NMNAT (synthesis of NAD) was measured in a continuous coupled enzyme assay by monitoring the increase in absorbance at 340 nm caused by the reduction of NAD to NADH as described [62]. Briefly, the reaction was performed at 37 °C in 16 nM semicarbacide-HCl, 0.625% (v/v) ethanol, 30 nM HEPES buffer (pH 7.4), 12.25 nM MgCl2, 1.17 mM ATP, 15 U yeast alcohol dehydrogenase (Sigma, St. Louis, Missouri, United States), purified recombinant NMNAT, and was initiated by adding NMN to a final concentration of 0.625 mM. The activity is determined from the linear progression curve using the following formula:
Retina sections and TEM. Flies of different ages were dissected and fixed at 4 °C in 2% paraformaldehyde; 2% glutaraldehyde; 0.1 M sodium cacodylate; 0.005% CaCl2 (pH 7.2), and postfixed in 2% OsO4. The 200 nm–thick sections of retina were stained with 1% toludine blue O, 1% sodium tetraborate (Electron Microscopy Sciences, Hatfield, Pennsylvania, United States). The 50-nm thin sections were stained with 4% uranyl acetate and 2.5% lead nitrate. Synaptic features of laminae were scored double-blind by several observers. For photoreceptor terminal quantification, photoreceptor terminals were identified by the presence of capitate projections [27]. In all electron microscopy analyses, we analyzed samples from at least four different animals per genotype. Immunocytochemistry. Eye discs, third instar larval fillets, and larval, pupal, and adult brains were fixed in phosphate buffered saline (PBS) with 3.5% formaldehyde for 15 min and washed in phosphate buffered saline with 0.4% Triton X-100, or with 0.2% Tween 20 for larval neuromuscular junction preparations. Antibody dilutions used: anti-NMNAT 1:1,000; anti-Armadillo 1:200; mAb nc82 1:100; anti-Actin mAb C4 1:200 (ICN Biomedicals, Costa Mesa, California, United States); and TOTO3 1:2,000 (Molecular Probes, Eugene, Oregon, United States). Anti-HRP and secondary antibodies conjugated to Cy3, Cy5, or Alexa 488 (Jackson ImmunoResearch, West Grove, Pennsylvania, United States; and Molecular Probes) were used at 1:250. All antibody incubations were performed at 4 °C overnight in the presence of 5% normal goat serum. Image acquisition and processing. Images from fluorescently labeled specimens were taken on a Zeiss LSM510 confocal microscope (Zeiss, Oberkochen, Germany) and processed using Amira 3.0 (TGS, San Diego, California, United States) and Adobe Photoshop 7.0 (Adobe Systems, San Jose, California, United States). Mosaic analyses. We used the MARCM technique [63] to analyze the localization of various proteins in nmnat mutant photoreceptor cells compared to their wild-type neighbors. All eye discs and laminae shown with 50% mutant photoreceptor terminals are from animals of the following genotype: y w eyFLP GMR-lacZ; P{{w+=UAS-mCD8::GFP.L}LL4 / GMR-GAL4; FRT82B nmnat/ FRT82B P{w+=tub-GAL80}. The negatively marked mutant eye disc clones in Figure S2 are from animals of the following genotype: y w eyFLP GMR-lacZ; FRT82B nmnat/ FRT82B P{w+mC=Ubi-GFP.nls}. Figure S1: Genomic and cDNA Rescue of the Neurodegeneration Phenotypes Caused by Loss of nmnat (A–F) ERG recordings of mutant photoreceptors (A), photoreceptors expressing the CG13645 genomic DNA (C), or photoreceptors expressing CG13645 cDNA driven by GMR-GAL4 in the nmnat1 mutant background (E). Both genomic DNA and cDNA expression rescue the magnitude of depolarization and on/off transients. The genotypes are marked at the top of each column. (B), (D), and (F) Retinal structures of each genotype. Both genomic DNA and cDNA expression restore the ommatidial morphology. (G–I) TEM micrographs of lamina cartridges of each genotype. Both genomic DNA and cDNA expression restore the photoreceptor terminal structure and organization. Demarcating glia are colored blue and photoreceptor terminals green. Scale bar in (G) for (G–I) indicates 1 μm. (J–O) Individual terminals boxed in (G–I). The active zone structures are well organized with defined platform structures (arrowheads), compared to the amorphous structures in the mutant terminals (arrows in J and K). Scale bar in (J) for (J–N) indicates 200 nm. (8.8 MB TIF) Click here for additional data file.(8.6M, tif) Figure S2: Polyclonal Antibodies Specifically Recognize NMNAT Protein Mosaic analysis of third instar larval eye disc. Wild-type control (iso) or Δ4790–1, Δ4790–2, nmnat1, or nmnat2 mutant clones are negatively marked. GFP marks the wild-type patch. Eye discs are labeled with NMNAT antibody and TOTO3 to reveal the nuclei. In Δ4790–1, Δ4790–2, nmnat1, or nmnat2 mutant clones, NMNAT staining is dramatically reduced. The level of reduction in staining in nmnat1 or nmnat2 clones is similar to the level in Δ4790–1 or Δ4790–2 clones, suggesting that nmnat1 and nmnat2 are likely protein null alleles. Scale bars indicate 5 μm. (8.3 MB TIF) Click here for additional data file.(8.1M, tif) Figure S3 Click here for additional data file.(1.2M, tif) Figure S4: NAD Synthesis Pathway NAD can be synthesized through the de novo pathway from L-tryptophan, or two salvage pathways from either nicotinic acid (Na) or nicotinamide (Nam). The fly homologs identified based on sequence homology are shown in red. (2.6 MB TIF) Click here for additional data file.(2.6M, tif) Table S1: Rescue Loss of nmnat Phenotypes with nmnat cDNA Both the wild-type and the inactive enzymes can rescue the morphological and physiological phenotypes of nmnat mutant photoreceptors. However, only the wild-type NMNAT, but not the enzymatically inactive NMNAT, can rescue the organismal lethality caused by loss of nmnat. (33 KB DOC) Click here for additional data file.(34K, doc) Acknowledgments We would like to thank Craig Montell, the Bloomington Stock Center, and the University of Iowa Developmental Studies Hybridoma Bank for reagents. We thank Hui-Chen Lu, Hamed Jafar-Nejad, and Hiroshi Tsuda for critical reading of the manuscript. Abbreviations
Footnotes ¤ Current address: Department of Physiology and Green Center Division for Systems Biology, UT Southwestern Medical Center at Dallas, Dallas, Texas, United States of America Competing interests. The authors have declared that no competing interests exist. Author contributions. RGZ and HJB conceived and designed the experiments. RGZ, YC, PRH, YZ, SQM, KLS, and PV performed the experiments. RGZ, PRH, and HJB analyzed the data. RGZ, PRH, SQM, KLS, and PV contributed reagents/materials/analysis tools. RGZ, PRH, KLS, and HJB wrote the paper. Funding. PRH was supported by a European Molecular Biology Organization (EMBO) long-term fellowship and PV by a Belgian American Educational Foundation (BAEF) fellowship. RGZ, PRH, KLS, PV, and HJB are supported by the Howard Hughes Medical Institute (HHMI). HJB is an HHMI investigator. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||||||||||||||||||||
J Physiol. 2001 Aug 1; 534(Pt 3):627-39.
[J Physiol. 2001]Neuron. 2003 Jul 17; 39(2):217-25.
[Neuron. 2003]J Neurosci. 2000 Feb 15; 20(4):1333-41.
[J Neurosci. 2000]Cell Death Differ. 2003 Feb; 10(2):260-1.
[Cell Death Differ. 2003]J Neurol Sci. 1992 Jun; 109(2):140-7.
[J Neurol Sci. 1992]Eur J Neurosci. 1995 Jul 1; 7(7):1641-50.
[Eur J Neurosci. 1995]Proc Natl Acad Sci U S A. 2000 Oct 10; 97(21):11377-82.
[Proc Natl Acad Sci U S A. 2000]Nat Neurosci. 2001 Dec; 4(12):1199-206.
[Nat Neurosci. 2001]Eur J Neurosci. 2005 Jan; 21(1):271-7.
[Eur J Neurosci. 2005]Science. 2004 Aug 13; 305(5686):1010-3.
[Science. 2004]J Cell Biol. 2005 Aug 1; 170(3):349-55.
[J Cell Biol. 2005]Nat Neurosci. 2001 Dec; 4(12):1199-206.
[Nat Neurosci. 2001]Neuron. 2005 Apr 21; 46(2):219-32.
[Neuron. 2005]Neuron. 2003 Nov 13; 40(4):733-48.
[Neuron. 2003]Development. 2000 Feb; 127(4):851-60.
[Development. 2000]Proc Natl Acad Sci U S A. 1967 Sep; 58(3):1112-1119.
[Proc Natl Acad Sci U S A. 1967]Curr Biol. 2006 Sep 19; 16(18):1835-43.
[Curr Biol. 2006]Physiology (Bethesda). 2004 Oct; 19():262-70.
[Physiology (Bethesda). 2004]Proc Natl Acad Sci U S A. 2003 Sep 16; 100(19):10860-5.
[Proc Natl Acad Sci U S A. 2003]Genetics. 2004 Jun; 167(2):761-81.
[Genetics. 2004]J Biol Chem. 2001 Jan 5; 276(1):406-12.
[J Biol Chem. 2001]J Biol Chem. 2003 Apr 11; 278(15):13503-11.
[J Biol Chem. 2003]Neuroscience. 2005; 135(4):1107-18.
[Neuroscience. 2005]J Biol Chem. 2001 Jan 5; 276(1):406-12.
[J Biol Chem. 2001]J Biol Chem. 2003 Apr 11; 278(15):13503-11.
[J Biol Chem. 2003]Proc Natl Acad Sci U S A. 1970 Nov; 67(3):1156-63.
[Proc Natl Acad Sci U S A. 1970]J Neurosci. 2000 Jan 15; 20(2):649-59.
[J Neurosci. 2000]Acta Anat (Basel). 1998; 162(2-3):85-94.
[Acta Anat (Basel). 1998]Annu Rev Neurosci. 1995; 18():283-317.
[Annu Rev Neurosci. 1995]Cell. 1988 Aug 26; 54(5):723-33.
[Cell. 1988]Proc Natl Acad Sci U S A. 1997 Nov 11; 94(23):12682-7.
[Proc Natl Acad Sci U S A. 1997]Development. 1994 Aug; 120(8):2121-9.
[Development. 1994]Science. 2004 Aug 13; 305(5686):1010-3.
[Science. 2004]J Cell Biol. 2005 Aug 1; 170(3):349-55.
[J Cell Biol. 2005]Nat Neurosci. 2001 Dec; 4(12):1199-206.
[Nat Neurosci. 2001]Nat Neurosci. 2001 Dec; 4(12):1199-206.
[Nat Neurosci. 2001]Proc Natl Acad Sci U S A. 1970 Nov; 67(3):1156-63.
[Proc Natl Acad Sci U S A. 1970]J Neurosci. 2000 Jan 15; 20(2):649-59.
[J Neurosci. 2000]Proc Natl Acad Sci U S A. 1993 Dec 1; 90(23):11157-61.
[Proc Natl Acad Sci U S A. 1993]Neuron. 2000 Apr; 26(1):169-79.
[Neuron. 2000]Curr Biol. 2004 Dec 14; 14(23):2076-85.
[Curr Biol. 2004]Invest Ophthalmol. 1966 Oct; 5(5):450-73.
[Invest Ophthalmol. 1966]Neuron. 2006 Jun 15; 50(6):869-81.
[Neuron. 2006]Neuron. 2000 Apr; 26(1):169-79.
[Neuron. 2000]J Neurosci. 2000 Jan 15; 20(2):649-59.
[J Neurosci. 2000]J Cell Sci. 2005 Apr 1; 118(Pt 7):1373-84.
[J Cell Sci. 2005]Bioessays. 2003 Jul; 25(7):683-90.
[Bioessays. 2003]Science. 2004 Aug 13; 305(5686):1010-3.
[Science. 2004]J Cell Biol. 2005 Aug 1; 170(3):349-55.
[J Cell Biol. 2005]Neuron. 2003 Jul 17; 39(2):217-25.
[Neuron. 2003]J Neural Transm. 2000; 107(1):1-29.
[J Neural Transm. 2000]Cell. 2005 Aug 26; 122(4):633-44.
[Cell. 2005]Neuron. 2006 Jun 15; 50(6):883-95.
[Neuron. 2006]Mol Biol Cell. 2006 Mar; 17(3):1075-84.
[Mol Biol Cell. 2006]Neuron. 2003 Nov 13; 40(4):733-48.
[Neuron. 2003]Neuron. 2005 Apr 21; 46(2):219-32.
[Neuron. 2005]Anal Biochem. 1995 Jun 10; 228(1):64-8.
[Anal Biochem. 1995]Trends Neurosci. 2001 May; 24(5):251-4.
[Trends Neurosci. 2001]